预约演示
更新于：2025-11-21
Amphotericin B
两性霉素B
更新于：2025-11-21
概要
基本信息
药物类型 小分子化药 |
别名 SinuNase、CM001、DKF-5122 + [14] |
作用方式 调节剂 |
作用机制 Ergosterol 调节剂(麦角固醇 调节剂) |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 (1958-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、合格传染病产品 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C47H73NO17 |
InChIKeyAPKFDSVGJQXUKY-INPOYWNPSA-N |
CAS号1397-89-3 |
关联
128
项与 两性霉素B 相关的临床试验NCT06525389
Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)
LAmB-FAST is a factorial randomized controlled trial simultaneously testing two interventions in one trial. LAmB-FAST seeks to inform treatment guidelines on the induction and maintenance therapy of HIV-associated talaromycosis (formerly called penicilliosis) and will answer the following three questions:
1. Is induction therapy using a single 10 mg/kg dose of liposomal amphotericin B (LAmB) is more effective than 14 days of the conventional deoxycholate amphotericin B (DAmB)?
2. Is adding flucytosine (5FC) to amphotericin B more effective than amphotericin B alone?
3. Is HIV viral load guided stopping of itraconazole maintenance therapy as effective as the current CD4 guided strategy in the prevention of talaromycosis relapse?
1. Is induction therapy using a single 10 mg/kg dose of liposomal amphotericin B (LAmB) is more effective than 14 days of the conventional deoxycholate amphotericin B (DAmB)?
2. Is adding flucytosine (5FC) to amphotericin B more effective than amphotericin B alone?
3. Is HIV viral load guided stopping of itraconazole maintenance therapy as effective as the current CD4 guided strategy in the prevention of talaromycosis relapse?
开始日期2025-12-01 |
申办/合作机构  Duke University [+4] |
NCT07191756
A Retrospective, Multicenter Cohort Study Comparing the Efficacy and Safety of Amphotericin B Versus Isavuconazole for the Treatment of Mucormycosis: Analysis of Institutional Data and Literature Review
Background:
Mucormycosis is a serious but rare fungal infection that requires rapid and effective treatment. The two main antifungal medicines used are amphotericin B and isavuconazole. However, more real-world data is needed to directly compare how well they work and how safe they are for patients.
What is the purpose of this study? The main goal of this research study is to compare the effectiveness and safety of amphotericin B versus isavuconazole in treating mucormycosis. Investigators will look at which medicine leads to better survival rates and fewer serious side effects.
How will the study be done? This is a retrospective study. This means investigators will look back at information that has already been collected. Investigators will analyze data from the medical records of patients who were treated for mucormycosis at three hospitals. Investigators will also review and combine findings from relevant studies published on PubMed.
What will the researchers measure?
Investigators will measure and compare:
How long patients survived after treatment (survival rates).
Whether the infection was successfully cured or controlled (treatment response).
What kinds of side effects (like kidney problems or liver issues) patients experienced with each medicine.
What are the possible benefits of this study? This study will not directly benefit the participants whose records are reviewed. However, investigators hope that what investigators learn will help doctors make better treatment decisions for future patients with mucormycosis by providing clearer evidence on the best choice of medicine.
Mucormycosis is a serious but rare fungal infection that requires rapid and effective treatment. The two main antifungal medicines used are amphotericin B and isavuconazole. However, more real-world data is needed to directly compare how well they work and how safe they are for patients.
What is the purpose of this study? The main goal of this research study is to compare the effectiveness and safety of amphotericin B versus isavuconazole in treating mucormycosis. Investigators will look at which medicine leads to better survival rates and fewer serious side effects.
How will the study be done? This is a retrospective study. This means investigators will look back at information that has already been collected. Investigators will analyze data from the medical records of patients who were treated for mucormycosis at three hospitals. Investigators will also review and combine findings from relevant studies published on PubMed.
What will the researchers measure?
Investigators will measure and compare:
How long patients survived after treatment (survival rates).
Whether the infection was successfully cured or controlled (treatment response).
What kinds of side effects (like kidney problems or liver issues) patients experienced with each medicine.
What are the possible benefits of this study? This study will not directly benefit the participants whose records are reviewed. However, investigators hope that what investigators learn will help doctors make better treatment decisions for future patients with mucormycosis by providing clearer evidence on the best choice of medicine.
开始日期2025-05-15 |
申办/合作机构  广西医科大学 [+1] |
ChiCTR2500100402
The efficacy and safety of Amphotericin B Cholesterol Sulfate Complex for Injection versus Voriconazole in the empiric treatment of invasive fungal infections in critically ill patients:A multicentre RCT study
开始日期2025-05-01 |
申办/合作机构- |
100 项与 两性霉素B 相关的临床结果
登录后查看更多信息
100 项与 两性霉素B 相关的转化医学
登录后查看更多信息
100 项与 两性霉素B 相关的专利（医药）
登录后查看更多信息
22,404
项与 两性霉素B 相关的文献（医药）2026-04-01·PARASITOLOGY INTERNATIONAL
Post-neurosurgical meningitis by Naegleria fowleri and Staphylococcus aureus in Ecuador: A case report
Article
作者: Neira, V ; Montalvo, Eduardo ; Zambrano, Nery Giler ; Fuertes-Flores, Byron ; Castro-Lalangui, E ; García-Díaz, Génesis ; Guevara-Bahamonde, Tatiana ; Pico, Diego Álvarez ; Lara-Cazorla, Camila ; Rivadeneira, E ; Echeverría-Garcés, Gabriela ; Cano-Pérez, Eder ; Páez, M
This report describes the first documented case in Ecuador of primary amoebic meningoencephalitis caused by Naegleria fowleri, in coinfection with methicillin-resistant Staphylococcus aureus (MRSA) associated with a ventriculoperitoneal shunt (VPS). A 23-year-old male with a history of severe traumatic brain injury developed central nervous system infection symptoms after VPS placement. Despite targeted antibiotics for MRSA, clinical deterioration continued. Whole genome sequencing confirmed N. fowleri, prompting antiparasitic treatment with amphotericin B and fluconazole, resulting in partial improvement. This case underscores the need to consider rare pathogens in atypical neurological cases and highlights the diagnostic value of genome sequencing in complex infections.
2026-02-01·DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Efficacy of liposomal amphotericin B for treating post-kala-azar dermal leishmaniasis (PKDL): A systematic review and single-arm meta-analysis
Review
作者: Lopes, Fabiana Castro Porto Silva ; Mendes, Beatriz Ximenes ; Husain, Noor ; Cavalcante, Deivyd Vieira Silva ; Amorim, Sarah Soares ; Mohan, Lalit ; Santos, Ana Clara Felix de Farias ; Ndikuryayo, Christian ; de Oliveira, Lilia Maria Lima ; Borrigueiro, Luciana ; Rosa, Lyria de Oliveira
BACKGROUND:
Post-kala-azar dermal leishmaniasis (PKDL) is a skin condition that can become a complication in about 15 % of patients who have had kala-azar. Despite its significance, treatment options for PKDL are still limited. This systematic review and meta-analysis aim to evaluate the efficacy of amphotericin B for this condition.
METHODS:
PubMed, Embase, Cochrane, and Web of Science databases were searched for randomized controlled trials (RCTs) that reported the efficacy of Liposomal Amphotericin B in the treatment of PKDL. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Events per 100 observations with 95 % confidence intervals were performed for outcomes.
RESULTS:
Nine studies with 639 patients were included, the treatment durations ranging from 7 to 60 days. The mean age ranged from 9.2 to 31.0 years, and 359 patients were male. The PKDL treatment with liposomal amphotericin B resulted in a cure rate of 91.36 % (95 % CI: 76.60-97.15). However, a relapse was observed in 11.42 % (95 % CI: 6.20-20.8) of patients. Adverse events were common, with hepatic enzyme elevation (ALT/AST) being the most frequent (61.75 %; 95 % CI: 21.81-90.33), followed by fever in 29.93 % of cases (95 % CI: 5.09-77.30). Among the more serious side effects, decreased serum potassium was observed in 19.27 % (95 % CI: 3.84-58.82), and increased serum creatinine, indicative of nephrotoxicity, occurred in 15.08 % (95 % CI: 3.97-43.27). Nausea or vomiting, although less severe, affected 12.36 % of patients (95 % CI: 4.81-28.25).
CONCLUSIONS:
These findings highlight that while liposomal amphotericin B is a potent therapeutic option for PKDL, its administration requires careful management and clinical vigilance to optimize outcomes and minimize risks.
2026-02-01·DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Disseminated cutaneous leishmaniasis with mucosal involvement in a patient with HTLV-1 infection: A case report
Article
作者: Farfán-Garcés, Isabel ; Mendivil-Tuchia de Tai, Sabina ; Cáceres-Bernaola, Ursula ; Sánchez Morales, Silvya ; Aguirre-Quispe, Wilfor
A case in Peru highlights the challenges of treating cutaneous leishmaniasis, a parasitic disease endemic to the region. A 44-year-old farmer presented with disseminated cutaneous leishmaniasis with mucosal involvement, further complicated by co-infection with HTLV-1, an unusual combination in Peru. Initial treatment with Amphotericin B was interrupted due to neuromuscular symptoms, causing disease recurrence. Serology later confirmed the HTLV-1 co-infection. After a comprehensive regimen including meglumine antimoniate, clindamycin, ceftriaxone, imiquimod, and pentoxifylline, the patient's lesions fully re-epithelialized within 30 days. The case emphasizes the necessity of treatment adherence and specialized follow-up to manage complex co-infections effectively.
229
项与 两性霉素B 相关的新闻（医药）2025-11-19
每年11月18日至24日，全球都会迎来一个特殊的“健康警报周”——世界提高抗微生物药物耐药性认识周。微生物是肉眼无法看到的微小生物体，在自然界中广泛存在，包括细菌、病毒、真菌和寄生虫等。这些微生物一旦进入人体，会引发不同种类的感染。而人类与之对抗的武器，就是抗微生物药物，如各类抗生素等。然而，随着药物的使用日益广泛，微生物通过随机突变获得耐药性，即在原本用于抑制或者杀灭它的特定药物存在，或保持既往有效浓度的情况下，仍能存活或生长的能力。这不仅使得常见的感染更难治疗，危害患者的个人健康，也对全球公共卫生水平造成了威胁。[1]
*图片由AI生成
当前，致病真菌对药物的耐药性正以惊人的速度攀升[2]。当真菌不断“进化”、抗真菌药物的疗效不断减弱，侵袭性真菌病这类严重感染的治疗将更加困难，进一步增加疾病的流行与死亡的风险[3]。
那么，面对愈发“狡猾”的真菌，我们该如何应对？
2025年世界提高抗微生物药物耐药性认识周的主题给出了明确指引：“立即行动：守护当下，保障未来”。这不仅是呼吁，更是“双管齐下”的行动号角：
合理使用现有药物，尽量减少或避免真菌的耐药与突破；
研发“新武器”，让治疗永远有“后手”。
如此，才能稳住防线，不让今天的感染成为明天的灾难。
规范用药，守住第一道防线
真菌的耐药性有两类[4]：天然耐药，与真菌物种相关，与药物暴露无关；而获得性耐药，是长期暴露于某种药物（通常是抗真菌药物或其结构类似物）后基因突变而获得。抗真菌药物的不当和过度使用是导致获得性耐药产生的重要因素之一[5]。因此需要医生精准诊断、对症下药，给予适当的抗真菌药物，且足剂量和足疗程但不滥用，杜绝不必要的预防性用药；而患者也不能随意用药和停药。这套策略被称为“抗真菌药物管理计划”[5]。该计划简单来说就是“让每一粒药都用在刀刃上”，最终为所有可能需要的患者留住希望。
安全剂型，点亮耐药困境中的曙光
当传统药物疗效欠佳时，科学界的答案很明确：不断研发，让真菌追不上科技进步的脚步。
传统两性霉素B抗真菌谱广、耐药罕见[6]，但传统制剂由于其毒副作用大，难以足剂量使用，影响治疗效果[7]。为提升两性霉素B的疗效及安全性，科研人员成功开发出两性霉素B脂质体剂型（L-AmB）。L-AmB改良后优势显著，不仅延续了传统制剂广谱强效的抗真菌实力，还通过靶向递送机制降低了毒副作用，提高了用药安全性，为危重患者提供了可靠的治疗选择，成为应对耐药真菌感染的关键力量[8]。
与此同时，科学家们也在积极研发作用于全新靶点的新型抗真菌药物，为未来储备更多“新武器”。
抗真菌药物耐药性的上升是一场“静悄悄的风暴”。在这场人与微生物的拉锯战中，规范用药是盾，创新药物是矛。通过医患同心、科学用药、持续创新——我们有能力合理运用抗真菌资源，为生命在危急时刻带来希望。
参考文献：
[1] 世界卫生组织https://www.fao.org/antimicrobial-resistance/background/faq/zh/
[2] Branda F, Petrosillo N, Ceccarelli G, et al. Antifungal Agents in the 21st Century: Advances, Challenges, and Future Perspectives. Infect Dis Rep. 2025;17(4):91. Published 2025 Aug 1. doi:10.3390/idr17040091
[3] 世界卫生组织官网，世界提高抗微生物药物耐药性认识周https://www.who.int/zh/campaigns/world-amr-awareness-week#:~:text=%E6%AF%8F%E5%B9%B4%E5%9C%A811%E6%9C%8818,%E4%B8%80%E6%AD%A5%E5%87%BA%E7%8E%B0%E5%92%8C%E8%94%93%E5%BB%B6%E3%80%82
[4] Vitiello A, Ferrara F, Boccellino M, Ponzo A, Cimmino C, Comberiati E, Zovi A, Clemente S, Sabbatucci M. Antifungal Drug Resistance: An Emergent Health Threat. Biomedicines. 2023; 11(4):1063. https://doi.org/10.3390/biomedicines11041063
[5] Shelke YP, Bankar NJ, Bandre GR, Hawale DV, Dawande P. An Overview of Preventive Strategies and the Role of Various Organizations in Combating Antimicrobial Resistance. Cureus. 2023;15(9):e44666. Published 2023 Sep 4. doi:10.7759/cureus.44666
[6] Cavassin, F. B., Queiroz-Telles, F., Bau´-Carneiro, J. L., & Vilas-Boas, R. R. (2021). Sixty years of Amphotericin B: An overview of the main antifungal agent used to treat invasive fungal infections. Infectious Diseases and Therapy, 10(1), 115–147. https://doi.org/10.1007/s40121-020-00382-7
[7] 孔旭东, 王晓星, 陈玥, 等. 两性霉素B不同制剂的药学特性和临床应用 [J]. 临床药物治疗杂志, 2022, 20(7):7-12.
[8] 冯赫宣, 李佩珊, 刘懿萱, 等. 脂质体的研究与应用进展[J]. 药学进展, 2024, 48(10): 725.
关于吉利德科学
吉利德科学是一家生物制药公司，成立三十多年来，探索并实现了多个医学上曾认为不可能实现的突破，旨在为公众创造一个更健康的世界。公司致力于推动药物革新，以预防和治疗HIV、病毒性肝炎、癌症和炎性疾病等可能威胁生命的疾病。吉利德在全世界超过35个国家和地区运营，总部位于美国加利福尼亚州福斯特市。
2017年，吉利德正式开始在中国的商业运营，从病毒性肝炎、HIV防治，到抗真菌感染和肿瘤领域，我们承诺为国内的重疾患者提供创新的治疗手段及方案，助力实现“健康中国”的宏伟目标。短短几年，已有十三个吉利德全球领先的药物在中国获批，其中八个药物已被列入国家医保目录，让更多患者接受创新药物治疗、重回健康生活成为可能。与此同时，吉利德还在中国大力推动研发团队和能力的建设，以期实现更多三期临床在中国的同步开展，帮助加速创新疗法的审批，以更早惠及更多有需要的患者。
2025-11-18
11月14日，《Nature》刊登了一项来自日本的大规模研究，系统分析了全国造血干细胞移植（HSCT）的真实医疗费用，涵盖几乎所有住院与门诊支出。
随着这项权威数据的公布，一个现实问题也随之被更多患者和家属关注：日本与中国在造血干细胞移植费用上究竟有哪些差异？哪一方更具成本优势？在技术水平和治疗路径上又是否存在明显不同？
本文基于日本国家健康保险数据库（NDB）中19,500例HSCT患者的真实费用数据，并结合中国目前公开资料及临床普遍收费区间，对比两国在费用构成、供体来源、年龄差异、医疗中心经验等关键因素的不同，为读者呈现一个更加全面、客观的对照分析。
1
先看结论：两国造血干细胞费用速览
整体趋势十分清晰：日本的造血干细胞移植总费用整体上略低于国内多数三甲医院的平均水平。
从目前公开数据来看，中国的造血干细胞移植平均费用大致在30–60万元区间；
而日本的平均费用换算成人民币大概在17-50万人民币之间。
但两国费用结构截然不同。国内的主要支出集中在住院费用和药物费用，而日本的最大成本则来自输血相关项目。
下面我将从不同维度逐一展开分析。
2
总体费用对比：日本略低于国内，但结构差异明显
1.自体造血干细胞移植费用对比
国家
3个月费用
1年费用
人民币估算（约）日本
$15,660
$24,195
约11万 – 17万中国（多数医院）
20–40万
（一般无需持续高额费用）
20–40万
主要原因包括药品价格较低且医保统一定价，而国内强化化疗、支持治疗及住院周期往往更长。
2.异基因移植费用对比
供体类型
日本3个月费用
日本1年费用
日本费用（人民币）
中国常规费用（人民币）骨髓供体（BMT）
$20,565
$33,904
约15–24万
60–100万外周血供体（PBSCT）
$17,807
$30,500
约13–22万
60–100万脐带血移植（CBT）
$41,935
$62,683
约30–46万
80–120万（部分中心更高）
在中国，即便最常见的外周血供体移植（亲缘/非亲缘），总费用通常在60–120万。
而日本大多数移植类型的费用在30万人民币以内（只有脐带血成本接近国内高值）。
3
费用构成差异：日本“输血成本最高”，中国“住院＋药物”占主要部分
日本费用结构特点（基于 NDB 真实世界数据）
1.输血费用占比最高（约10–30%）：日本输血制品价格高、使用量大，是整体费用的最大来源。像脐带血移植（CBT）因造血重建慢、并发症多，对输血依赖更大，费用进一步上升。
2.药物费用相对稳定，免疫抑制剂成本波动小：抗真菌药物价格偏高，但整体药物支出占比仍不及输血费用。
3.医疗服务价格统一、波动小：日本采用全国统一医保定价，医生操作费、检查费等费用透明度高、差异小。
4.大规模移植中心成本更低：年手术量≥30例的大中心在输血管理、感染控制及并发症处理方面更成熟，可明显降低总体支出。
中国费用结构特点（基于国内三甲与移植中心普遍情况）
1.住院费用+药物费用占主要部分：移植仓收费高、住院周期长（通常3–4个月），住院费成为最大支出。
2.抗感染药物成本高：两性霉素 B、伏立康唑等抗真菌药物占比极大，是费用的核心推动因素之一。此外中国在感染管理中药物依赖度更高。
3.免疫抑制剂与生物制剂价格高：尤其是用于预防或治疗 GVHD 的生物制剂，使整体药物费用进一步上升。
4.输血费用占比相对较小：虽然输血是移植过程中必要环节，但在总费用中所占比例明显低于日本。
4
供体类型对费用影响：两国趋势一致，但差距不同
在供体类型对费用的影响上，中日趋势一致，脐带血（CBT）移植最贵。
日本CBT费用几乎是其他供体的两倍，主要因为植入延迟、输血多、感染风险高。
中国CBT同样最贵，而且整体费用更高，儿童患者常需多份脐带血，供体配型、采集、保存及并发症治疗增加了总成本。
总体来看，两国都是CBT最贵，但日本更倾向使用脐带血，而中国多数使用亲缘或非亲缘外周血供体。
5
年龄与费用差异：两国均呈“儿童和老年更贵”
在年龄与费用的关系上，中日两国呈现出相似规律，即儿童和老年患者的移植费用明显高于中青年群体。
日本NDB数据显示，0–19岁的患者费用最高，自体移植甚至可达到成人的1.5倍；70岁以上患者费用位居第二，随着年龄的增大，移植成本也随之增加。
中国临床实践也呈现相同趋势：儿童因需强化支持治疗而增加费用，而老年患者往往伴有多种合并症，感染风险高，导致治疗和住院成本显著上升。
6
医院移植经验影响费用：日本差异更明显
医院的移植经验对费用的影响在日本尤其明显。研究显示，年均移植量达到30例及以上的高容量中心，整体费用最低，尤其是脐带血移植，低容量与高容量中心之间的费用差距可超过17,000美元。
这反映了经验丰富的中心在并发症管理、输血控制及住院效率方面的优势。
在中国，大型移植中心如北大人民医院、苏州系统医学中心、华西医院、浙大邵逸夫医院和协和医院等，费用相对稳定，而小规模中心因复发率和感染率较高，总体成本往往被拉高。
7
为什么日本总体费用低？（核心因素总结）
原因
日本优势
中国现状医保统一价格体系
价格透明、全国统一
医院差异大，药价差别明显抗感染药物成本低
长期医保谈判降低价格
特殊抗真菌及生物制剂价格高住院周期更短
统一路径管理
国内住院时间普遍更长大规模移植中心比例更高
降低输血及并发症
中心差异大脐带血库成熟
CBT更普遍、流程稳定
CBT资源有限、成本高
8
结语
总体来看，日本的造血干细胞移植（HSCT）费用略低于国内，尤其是在外周血和骨髓移植方面。无论中日，脐带血移植始终是最昂贵的模式。
两国费用结构存在明显差异：日本以输血费用为主，而中国则以抗感染药物和住院费用占比最高。高容量、大型中心能够显著降低移植成本，这一点在两国均适用。同时，儿童和老年患者的费用普遍偏高。
对于考虑海外医疗或关注中日医疗体系差异的患者而言，仍需综合考虑适应证、等待时间、语言沟通及供者来源等因素，这些加起来可能两者的费用就差不多了。
信息来源：nature
本文仅作健康科普，不能替代医院的检查和治疗。内容不代表任何机构立场，亦无商业推荐意图。部分内容由AI辅助生成，并经人工审核整理。
BREAK AWAY
往期推荐
01
警告！韩国史上最大医疗乱象曝光：干细胞治疗转诊团伙回扣达36亿、77人被捕，提醒身边人提高警惕，别再轻信海外疗法!
02
科普 | 解放军总医院李平教授解答：干细胞疗法在治疗糖尿病肾病中的原理机制与最新临床研究
03
上海长征医院殷浩教授发声：糖尿病干细胞疗法最快明年上市！全球已有三个团队实现功能性治愈
临床研究
2025-11-17
Journal of Antimicrobial Chemotherapy Volume 80, Issue 7抗菌化疗杂志 80卷 7期
https://academic.oup.com/jac/issue
REVIEWS（综述）
1
The role of antimicrobial prophylaxis in brachytherapy for prostate, breast and gynaecological cancer: a narrative review
抗生素预防用药在前列腺、乳腺及妇科癌症近距离治疗中的作用：叙述性综述
Konstantinos Alexakis and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1753–1771,
2
To be or not to be: the non-antimicrobial properties of common antimicrobials
生存还是毁灭：常见抗菌药物的非抗菌特性
Shivakumar Narayanan and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1772–1783,
SYSTEMATIC REVIEWS（系统综述）
3
Antibiotic-induced Bartter-like syndrome: a systematic review
抗生素诱发的巴特综合征样表现：系统综述
Megha Priyadarshi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1784–1791,
4
Liposomal amphotericin B prophylaxis in paediatrics: a systematic review
两性霉素B脂质体预防性用药在儿科中的应用：系统综述
Emma V Thorley and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1792–1802,
ORIGINAL RESEARCH（论著）
5
Antibiotic use attributable to RSV infections during infancy—an international prospective birth cohort study
婴儿期呼吸道合胞病毒感染所致抗生素使用情况——一项国际前瞻性出生队列研究
Sarah F Hak and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1803–1812,
6
Plasmodium falciparum isolates: ex vivo drug response
恶性疟原虫分离株：体外药物反应
Edem Adika and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1813–1822,
7
Impact of hypoalbuminemia on patients receiving ertapenem combination therapy for methicillin-susceptible Staphylococcus aureus bacteraemia
低白蛋白血症对接受厄他培南联合疗法治疗甲氧西林敏感金黄色葡萄球菌菌血症患者的影响
Sunish Shah and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1823–1827,
8
Exploring community pharmacy professionals and general practitioners’ views on primary care communication and pathways to access antibiotics in England
探究英国社区药房专业人员和全科医生对初级保健沟通及获取抗生素途径的看法
Ming Xuan Lee and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1828–1836,
9
Decline of antimicrobial resistance in Pseudomonas aeruginosa bacteraemia following the COVID-19 pandemic: a longitudinal observational study
新冠疫情后铜绿假单胞菌菌血症抗菌药物耐药性的下降：一项纵向观察研究
Yulia Butscheid and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1837–1848,
10
Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy
意大利HIV感染者（HIV-RNA不可检测）特定合并症与抗逆转录病毒药物转换概率：一项回顾性分析
Alessandro Cozzi-Lepri and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1849–1859,
11
Model-based translation of the PKPD-relationship for linezolid and vancomycin on methicillin-resistant Staphylococcus aureus: from in vitro time–kill experiments to a mouse pneumonia model
基于模型转化利奈唑胺和万古霉素对甲氧西林耐药金黄色葡萄球菌的药代动力学-药效学关系：从体外时间杀菌实验到小鼠肺炎模型
Diego Vera-Yunca and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1860–1868,
12
Inner-mitochondrial membrane protein PfMPV17 is linked to P. falciparum in vitro resistance to the indoloquinolizidine alkaloid alstonine
线粒体内膜蛋白PfMPV17与恶性疟原虫对吲哚醌啉生物碱阿尔斯通宁的体外耐药性相关
J R Macdonald and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1869–1877,
13
Efficacy and tolerability of the combination of minocycline and metronidazole for macrolide-resistant Mycoplasma genitalium
米诺环素与甲硝唑联合治疗大环内酯类耐药生殖支原体感染的疗效和耐受性
Kay Htaik and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1878–1884,
14
Early use of the novel antifungal rezafungin: a case series and literature review
新型抗真菌药物瑞扎芬净的早期使用：病例系列报道及文献综述
H C Davidson and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1885–1892,
15
Optimal dosing of amoxicillin in obese and post-gastric bypass patients using a population pharmacokinetics-pharmacodynamics model approach
基于群体药代动力学-药效学模型方法确定阿莫西林在肥胖和胃旁路术后患者中的最佳剂量
Gisela Myrian de Lima Leite Dalla Rosa and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1893–1901,
16
Decreasing antimicrobial resistance in representative UK livestock species was associated with reduced total sales of antimicrobials in the last decade
过去十年，英国代表性家畜物种抗菌药物耐药性下降与抗菌药物总销量减少相关
Aliya El Nagar and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1902–1906,
17
An improved multiplex RT–quantitative PCR assay can reveal sex-specific activity of transmission-blocking drugs on ex vivo gametocytes from Plasmodium falciparum asymptomatic infections
一种改进的多重逆转录定量聚合酶链反应检测法可揭示性特异性抗疟疾传播阻断药物对恶性疟原虫无症状感染体外配子体活性的影响
Mariagrazia Ciardo and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1907–1914,
18
Population pharmacokinetics and thrombocytopenia risk assessment of linezolid in liver transplant recipients
利奈唑胺在肝移植受者中的群体药代动力学及血小板减少症风险评估
Xiaoping Shi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1915–1925,
19
Rapid susceptibility testing on urine for antimicrobial stewardship in general practice
全科实践中的尿液快速药敏试验助力抗菌药物管理
Patrick D J Sturm and Tanja Schülin
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1926–1932,
20
Efficacy of linezolid in monotherapy q12h versus q8h versus combined with daptomycin in the treatment of experimental endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus strains
利奈唑胺单药治疗每12小时一次与每8小时一次，以及与达托霉素联合治疗甲氧西林耐药和糖肽中介金黄色葡萄球菌菌株所致实验性心内膜炎的疗效
María-Alexandra Cañas and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1933–1941,
21
In vitro activity of NOSO-502, a novel-action antimicrobial, against clinical strains of Enterobacterales including MDR strains
新型作用机制抗菌药物NOSO-502对包括多重耐药菌株在内的肠杆菌科临床菌株的体外活性
Marie L G Attwood and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1942–1946,
22
Antibacterial activity of propylene glycol against Staphylococcus aureus and Staphylococcus epidermidis in neutral and mild acidic conditions
中性及弱酸性条件下，丙二醇对金黄色葡萄球菌和表皮葡萄球菌的抗菌活性
Nadiia Mosiichuk and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1947–1950,
23
Molecular characteristics of chromosome-mediated colistin resistance in foodborne Salmonella isolates in China
中国食源性沙门氏菌分离株染色体介导的多粘菌素耐药性的分子特征
Zeqiang Zhan and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1951–1963,
24
High azole non-wild type rates and nosocomial microsatellite typing aggregation of Wickerhamomyces anomalus in China according to a 12-year multicenter surveillance study
根据一项为期12年的多中心监测研究，中国异常威克汉姆酵母属唑类非野生型率高且医院内微卫星分型聚集
Zhengyu Luo and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1964–1971,
25
Repurposing antimalarials: pyrimethamine exhibits superior in vitro activity to metronidazole against Gardnerella while sparing Lactobacillus
抗疟药物再利用：乙胺嘧啶对加德纳菌的体外活性优于甲硝唑，且对乳酸杆菌无影响
Aliona S Rosca and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1972–1979,
26
Clinical characteristics and risk factors of tigecycline-induced acute pancreatitis in kidney transplant recipients: a retrospective study
肾移植受者替加环素诱发急性胰腺炎的临床特征及危险因素：一项回顾性研究
Lijuan Feng and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1980–1987,
27
Genomic characteristics of the multiresistant Acinetobacter baumannii global clone 1 reference strain A297/RUH875
多重耐药鲍曼不动杆菌全球克隆1型参考菌株A297/RUH875的基因组特征
Jonathan Koong and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1988–1992,
28
Comparison of a modified broth microdilution Sensititre™ SLOMYCOI assay with the CLSI-recommended agar disk elution method for antimicrobial susceptibility testing of Mycobacterium haemophilum
改良肉汤微量稀释Sensititre™ SLOMYCOI检测法与CLSI推荐的琼脂稀释法对嗜血杆菌属抗菌药物敏感性检测的比较
Doris Hillemann and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1993–1996,
29
Reversal of phenotypic resistance in multi-drug resistant carbapenemase-producing K. pneumoniae clinical isolates due to in vitro synergistic interactions between bacteriophages and antibiotics at clinically achievable concentrations
由于细菌噬菌体和抗生素在临床可达到浓度下的体外协同作用，多重耐药碳青霉烯酶产生肺炎克雷伯菌临床分离株的表型耐药性发生逆转
Paschalis Paranos and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1997–2006,
30
Antibiotic resistance and population structure of Staphylococcus epidermidis from prosthetic joint infections in Sweden and France
瑞典和法国假体关节感染表皮葡萄球菌的抗生素耐药性和群体结构
Sofie M Edslev and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2007–2015,
31
Lines on the line: evaluating the impact of antibiotic lock therapy versus catheter removal in the management of central vascular catheter infections
抗生素锁疗法与导管拔除术治疗中心血管导管感染的影响评估
Nischal Ranganath and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2016–2024,
32
Real-time FT-IR typing of Klebsiella pneumoniae: a flexible and rapid approach for outbreak detection and infection control
肺炎克雷伯菌实时傅里叶变换红外分型：一种灵活快速的暴发检测和感染控制方法
Ana Beatriz Gonçalves and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2025–2031,
33
Antibiotic stress affects the secretion and physicochemical features of extracellular vesicles produced by Helicobacter pylori
抗生素压力影响幽门螺杆菌产生的细胞外囊泡的分泌和物理化学特性
Paweł Krzyżek and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2032–2043,
34
A novel azithromycin resistance mutation in Mycoplasma genitalium induced in vitro
生殖支原体体外诱导产生的新型阿奇霉素耐药突变
Teck-Phui Chua and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2044–2050,
RESEARCH LETTERS（研究信函）
35
Posaconazole dosing of enteral formulations in infants and young children to achieve therapeutic concentrations
婴儿和幼儿肠内制剂泊沙康唑的给药剂量以达到治疗浓度
Jeffrey Harrington and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2051–2053,
36
Antimony used as rescue therapy in a kidney transplant recipient unresponsive to liposomal amphotericin B for chronic visceral leishmaniasis
两性霉素B脂质体治疗慢性内脏利什曼病无效的肾移植受者中使用锑剂作为挽救疗法
Natacha Mrozek and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2053–2056,
37
Is cefazolin an option for treatment of staphylococcal endogenous endophthalmitis?
头孢唑林是否可用于治疗葡萄球菌性内源性眼内炎？
Alexandra Morin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2057–2058,
LETTER TO THE EDITOR（致编辑的信）
38
Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre—a counterpoint
单用替考拉宁治疗肠球菌感染性心内膜炎：一家转诊中心的回顾性和比较研究——反驳观点
Miguel Villamarín and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2059–2060,
Journal of Antimicrobial Chemotherapy Volume 80, Issue 8
抗菌化疗杂志 80卷 8期
https://academic.oup.com/jac/issue
Review(综述)
1
World Health Organisation’s Bacterial Pathogen Priority List (BPPL) 2017 and BPPL 2024 to combat global antimicrobial resistance crisis: ‘challenges and opportunities’
世界卫生组织2017年和2024年用以应对全球抗菌药物耐药性危机的细菌病原体优先名单（BPPL）：“挑战与机遇”
Vazhayil Hari Krishnaprasad and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2061–2069
Original Research(论著)
2
Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5years of surveillance prior to approval for clinical use (2019–2023)
氨曲南/阿维巴坦对欧洲医疗中心肠杆菌科细菌的活性：临床批准前5年（2019-2023年）监测总结
Helio S Sader and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2070–2079
3
High feasibility of salivary therapeutic drug monitoring in linezolid, but lower feasibility in tedizolid: a single-dose study in healthy subjects and a monocentric prospective exploratory study in patients who received linezolid
利奈唑胺唾液治疗药物监测可行性高，但替地唑胺可行性较低：一项健康受试者单剂量研究和一项接受利奈唑胺患者单中心前瞻性探索性研究
Hitoshi Kawasuji and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2080–2091
4
Establishment and validation of downsized hollow-fibre infection model and pharmacokinetics/pharmacodynamics analysis of VAN on Enterococcus faecium
缩小版中空纤维感染模型的建立与验证及万古霉素对粪肠球菌的药代动力学/药效学分析
Yukitaka Hayashi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2092–2099
5
Four-month clofazimine regimen for susceptible pulmonary TB: a randomized clinical trial
为期4个月的氯法齐明方案治疗敏感型肺结核：一项随机临床试验
Nusrat Shafiq and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2100–2108
6
An ex vivo model to determine transmembrane clearance of antimicrobials during continuous renal replacement therapy
用于确定连续性肾脏替代治疗期间抗菌药物跨膜清除率的体外模型
Cole McGrath and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2109–2116
7
Optimization and improvement of the disc diffusion method for mucoid Pseudomonas aeruginosa
黏液型铜绿假单胞菌纸片扩散法的优化与改进
Aixin Wang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2117–2125
8
HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022
乌干达接受基于多替拉韦抗逆转录病毒方案的HIV感染者中HIV-1耐药性情况：2022年一项基于国家实验室使用剩余病毒载量样本的调查
Christine Watera and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2126–2134
9
Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women
与固定剂量相比，基于体重给药的CAP256V2LS（一种用于女性HIV预防的广谱中和抗体）群体药代动力学研究
Sharana Mahomed and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2135–2144
10
Gut microbiota and weight gain in people with HIV on integrase inhibitors: a five-year longitudinal study
接受整合酶抑制剂治疗的HIV感染者肠道微生物群与体重增加情况：一项为期五年的纵向研究
Javier García-Abellán and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2145–2157
11
Development of a ribavirin dosing regimen in transplant recipients with chronic hepatitis E virus infection: a population pharmacokinetic and -dynamic model
慢性戊型肝炎病毒感染移植受者利巴韦林给药方案的开发：一项群体药代动力学和药效学模型研究
Midas B Mulder and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2158–2168
12
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort
长效卡博特韦/利匹韦林在病毒受抑制的HIV感染者中的治疗中断有效性和预测因素：来自Icona队列的现实数据
Roberta Gagliardini and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2169–2178
13
Five-days-on-two-days-off (FOTO) versus daily bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV: a pilot randomized clinical trial
病毒受抑制的HIV感染者中，5天用药2天停药（FOTO）方案与每日比克替拉韦/恩曲他滨/丙酚替诺福韦方案的对比：一项初步随机临床试验
Hsin-Yun Sun and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2179–2186
14
Reliability of disc diffusion testing and molecular epidemiology of penicillin-susceptible Staphylococcus aureus bacteraemia
青霉素敏感金黄色葡萄球菌菌血症的纸片扩散试验可靠性和分子流行病学研究
Pernilla Kihlberg and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2187–2193
15
Outcomes of ceftriaxone 2g versus 1g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study
住院肺炎患者每日头孢曲松2克与1克疗效对比：一项全国性回顾性队列研究
Jumpei Taniguchi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2194–2202
16
Oleanolic acid derivative bardoxolone combats multidrug-resistant Staphylococcus aureus by destroying cell membrane and pyruvate metabolism pathway
齐墩果酸衍生物巴多昔隆通过破坏细胞膜和丙酮酸代谢途径对抗多重耐药金黄色葡萄球菌
Yun-Dan Zheng and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2203–2213
17
Evaluation of amoxicillin and benzylpenicillin therapy in early-onset neonatal sepsis: a pharmacometric external validation and simulation study
阿莫西林和苄青霉素治疗早期新生儿败血症的评估：一项药效计量学外部验证和模拟研究
Tom C Zwart and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2214–2225
18
48Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial
HIV感染者换用多替拉韦加拉米夫定治疗48周身体成分变化：DOLAM随机临床试验的计划子分析
Elisa de Lazzari and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2226–2233
19
The impact of inter-infection time on antimicrobial resistance profiles in women with multiple urinary tract infections over time
多次尿路感染女性患者感染间隔时间对抗菌药物耐药性特征的影响
Trenton Honda and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2234–2240
20
Development and evaluation of a novel rapid immunochromatographic assay for the detection of DHA-producing Enterobacterales
一种检测产DHA肠杆菌科细菌的新型快速免疫层析法的开发与评估
Christian Moguet and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2241–2246
21
Enterococcus faecium bacteraemia: a multicentre observational study focused on risk factors for clinical and microbiological outcomes
粪肠球菌菌血症：一项关注临床和微生物学结局风险因素的多中心观察性研究
Matteo Rinaldi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2247–2256
22
Indolocarbazoles as host-directed therapeutics against intracellular infections by methicillin-resistant Staphylococcus aureus
靛红咔唑类化合物作为宿主导向疗法对抗甲氧西林耐药金黄色葡萄球菌细胞内感染
Robin H G A van den Biggelaar and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2257–2268
23
Clinical validation of antimicrobial dosing regimens for continuous renal replacement therapy based on an ex vivo dosing algorithm
基于体外给药算法的连续性肾脏替代治疗抗菌药物给药方案的临床验证
Christina Koenig and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2269–2279
24
Novel integrative and conjugative elements carrying cfr(B) and cfr(C) linezolid resistance genes in Clostridioides difficile isolates from calves, Italy
意大利牛犊艰难梭菌分离株中携带cfr(B)和cfr(C)利奈唑胺耐药基因的新型整合性和接合性元件
Andrea Brenciani and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2280–2284
25
Characterization of Carbapenemase-producing Enterobacterales isolated from patients returning from Sub-Saharan Africa, France, 2015–2022
2015-2022年从撒哈拉以南非洲返回的法国患者中分离出的产碳青霉烯酶肠杆菌科细菌的特征
Corentin Poignon and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2285–2294
26
Penicillin-susceptible ST398 with strong biofilm-forming ability poses a significant threat to osteoarticular infections
具有强生物膜形成能力的青霉素敏感ST398型对骨关节感染构成重大威胁
Ye Jin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2295–2304
27
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB
贝达喹啉、德拉马尼和莫西沙星与不同剂量苏特唑利或德帕唑利联合用药治疗药物敏感型肺结核的心脏安全性
Simon E Koele and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2305–2313
28
Comparison of ceftolozane/tazobactam and meropenem in treating bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacterales: a single-centre, retrospective, real-world study
头孢托唑坦/他唑巴坦与美罗培南治疗产超广谱β-内酰胺酶肠杆菌科细菌所致血流感染的对比：一项单中心回顾性现实研究
Dimitrios Basoulis and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2314–2322
Research Letters(研究信件)
29
Dalbavancin as chronic suppressive therapy in a patient undergoing monthly apheresis: a case report with therapeutic drug monitoring
达巴万星作为每月进行血浆置换术患者的长期抑制治疗：一项带治疗药物监测的病例报告
Carlo Pallotto and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2323–2324
30
A novel methicillin-resistant Staphylococcus aureus lineage (ST4174) with an uncharacterized SCCmec variant identified in Korean pigs
韩国猪体内发现的一种带有未表征SCCmec变体的新型甲氧西林耐药金黄色葡萄球菌谱系（ST4174）
Hyeonwoo Cho and Kun Taek Park
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2325–2326
31
Time fixes everything, but not always: 10years of persistent PI mutations in the absence of pharmacological pressure—a case report
时间能治愈一切，但并非总是如此：无药物压力下持续10年的蛋白酶抑制剂突变——一例病例报告
Layla Pagnucco and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2327–2330
32
Carbapenem resistance in Escherichia marmotae: characterization of IncL plasmids carrying blaOXA-48
土拨鼠埃希菌的碳青霉烯耐药性：携带blaOXA-48的IncL质粒特征
Astrid Rasmussen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2330–2331
Letters to the Editor(致编辑的信)
33
Comment on: Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a tertiary university hospital
述评：产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究
Jianjun Li and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2332
34
Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a Tertiary University Hospital—right to reply—author’s response
产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究——作者回复
Gulhadiye Avcu
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2332–2333
Corrections(更正)
35
Correction to: Sofosbuvir as post-exposure prophylaxis for yellow fever–associated viscerotropic disease (YEL-AVD)
更正：索非布韦作为黄热病相关内脏热带病（YEL-AVD）暴露后预防用药
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2334
36
Correction to: Pandemic human-associated extended-spectrum β-lactamase-producing Escherichia coli lineages of ST38, ST131 and ST141 identified in Viennese dogs
更正：维也纳犬体内发现与人相关的大流行性产超广谱β-内酰胺酶大肠杆菌ST38、ST131和ST141谱系
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2335
37
Correction to: GP or ChatGPT? Ability of large language models (LLMs) to support general practitioners when prescribing antibiotics
更正：全科医生还是ChatGPT？大型语言模型（LLM）在全科医生开具抗生素处方时的辅助能力
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2336
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2
抗菌化疗杂志 80卷 增刊2期
https://academic.oup.com/jac/issue
SUPPLEMENT (补充)
CANWARD 2007-23
加拿大抗感染耐药监测项目（CANWARD）2007-2023年数据/报告
Foreword(前言)
1
The CANWARD studies: Canadian Antimicrobial Resistance Alliance (CARA) Canadian Hospital Ward Antibiotic Resistance Surveillance collection
加拿大抗感染耐药监测项目研究：加拿大抗微生物耐药联盟（CARA）加拿大医院病房耐药性监测数据集
James C Hurley and Jean-Yves Madec
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Page ii1
Supplement Papers(补充论文)
2
Seventeen years of the CANWARD study (2007–23)
加拿大抗感染耐药监测项目研究17年（2007-2023年）
George G Zhanel and Heather J Adam
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii2–ii4
3
Gram-positive pathogens from Canadian hospitals: 17years of results from the CANWARD study (2007–23)
来自加拿大医院的革兰氏阳性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023）
George G Zhanel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii5–ii14
4
Gram-negative pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007–23)
来自加拿大医院的革兰氏阴性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023）
George G Zhanel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii15–ii26
5
Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007–23)
加拿大医院耐甲氧西林金黄色葡萄球菌的特征：加拿大抗感染耐药监测项目研究的17年（2007-2023）
Anissa Brahami and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii27–ii34
6
Comparison of antimicrobial resistance and serotype patterns in Streptococcus pneumoniae from blood cultures and respiratory specimens in Canadian hospitals from the CANWARD study (2007–23)
加拿大抗感染耐药监测项目研究中加拿大医院血液培养和呼吸道标本中肺炎链球菌抗微生物药物耐药性和血清型的比较（2007-23）
Heather J Adam and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii35–ii44
7
Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007–23
加拿大医院中产生ESBL的大肠杆菌和肺炎克雷伯菌的比率增加：加拿大抗感染耐药监测项目研究17年，2007-2023
Philippe Lagacé-Wiens and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii45–ii53
8
Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007–23)
加拿大医院耐厄他培宁肠杆菌的特征：17年的加拿大抗感染耐药监测项目研究（2007-23）
Laura F Mataseje and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii54–ii61
9
Characterization of carbapenem-resistant Pseudomonas aeruginosa in Canadian hospitals: 6years of the CANWARD study (2018–23)
加拿大医院耐碳青霉烯假单胞菌的特征：6年的加拿大抗感染耐药监测项目研究（2018-23）
Melissa McCracken and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii62–ii71
10
Distribution and antimicrobial susceptibility profile of pathogens recovered from the bloodstream of Canadian patients: results from the CANWARD study (2007–23)
加拿大患者血液中病原菌的分布和药敏特征：来自加拿大抗感染耐药监测项目研究（2007-23）的结果
Andrew Walkty and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii72–ii82
Journal of Antimicrobial Chemotherapy Volume 80, Issue 9抗菌化疗杂志 80卷 9期
https://academic.oup.com/jac/issue
VIEWPOINT（观点）
1
Classifying patients with invasive fungal disease: towards a unified case definition?
侵袭性真菌病患者分类：能否达成统一的病例定义？
Mehmet Ergün and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2337–2343,
SYSTEMATIC REVIEW（系统综述）
2
Efficacy and safety of earlier switching to an oral antibiotic therapy for the treatment of Gram-positive bloodstream infections: a systematic review and meta-analysis
早期转换为口服抗生素治疗革兰氏阳性菌血流感染的疗效和安全性：一项系统综述和荟萃分析
ZhaoYi Tan and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2344–2360,
ORIGINAL RESEARCH（论著）
3
Determination of epidemiological cut-off values for Narasin, Salinomycin, Lasalocid and Monensin in Enterococcus faecium
屎肠球菌中那拉霉素、盐霉素、拉沙洛西钠和莫能菌素流行病学临界值的测定
Maria Laura Ferrando and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2361–2368,
4
Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era
四类耐药HIV感染者体内CXCR4嗜性病毒的持续存在及其在现代抗逆转录病毒治疗时代的临床影响
Rebecka Papaioannu Borjesson and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2369–2374,
5
Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeks
随机试验中96周内使用多替拉韦或对照抗逆转录病毒疗法对高血压和血压变化的影响
Parul Patel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2375–2383,
6
Comparative analysis of lipid profile changes in treatment-naïve people living with HIV on INSTI-based single-tablet regimens, BIC/FTC/TAF and DTG/3TC: real-world evidence from South Korea
基于整合酶抑制剂的单片复方制剂BIC/FTC/TAF和DTG/3TC在韩国初治HIV感染者中血脂谱变化的比较分析：来自现实世界的证据
So Yun Lim and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2384–2390,
7
A novel multilocus sequence typing scheme for Morganella spp.: population structure and introduction of quantitative metric for standardization of MLST scheme
摩根氏菌属的一种新型多位点序列分型方案：群体结构及引入用于标准化多位点序列分型方案的定量度量标准
Aymeric Jacquemin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2391–2398,
8
Genomic characterization of multidrug-resistant extended-spectrum β-lactamase-producing Vibrio cholerae O1 strains from 2022 cholera outbreak in Kenya
2022年肯尼亚霍乱疫情中产超广谱β-内酰胺酶的多重耐药霍乱弧菌O1株的基因组特征
Diana Imoli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2399–2407,
9
Impact of empiric anti-VRE therapy on survival in vancomycin-resistant enterococcal bloodstream infection
经验性抗万古霉素耐药肠球菌治疗对万古霉素耐药肠球菌血流感染患者生存率的影响
Tao-Hung Ou and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2408–2416,
10
Safety of topical tobramycin powder during operative treatment of fractures
骨折手术中使用局部妥布霉素粉末的安全性
Gregory M Schrank and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2417–2420,
11
Trimethoprim/sulfamethoxazole and risk of haemophagocytic lymphohistiocytosis (HLH): a literature review and disproportionality analysis using individual case safety reports from FAERS
复方磺胺甲恶唑与噬血细胞性淋巴组织细胞增多症（HLH）的风险：基于FAERS数据库个案安全报告的文献综述和比例失衡分析
Rinko Lau and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2421–2427,
12
Highly drug-resistant Vibrio cholerae harbouring blaPER-7 isolated from travellers returning to England
从返回英国的旅行者中分离出携带blaPER-7基因的高度耐药霍乱弧菌
Satheesh Nair and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2428–2432,
13
Overcoming antimicrobial resistance in Helicobacter pylori: the roles of collateral sensitivity and biofilm dynamics
克服幽门螺杆菌的抗菌药物耐药性：附带敏感性和生物膜动态的作用
Siddharth Singh and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2433–2441,
14
Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae
四种未接触过但对头孢地尔耐药的产NDM肺炎克雷伯菌所致血流感染的临床和微生物学分析
Maria Mazzitelli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2442–2446,
15
Synergistic effects of DHA27 combined with gentamicin against methicillin-resistant Staphylococcus aureus in vitro and in vivo
DHA27与庆大霉素联合对耐甲氧西林金黄色葡萄球菌的体内外协同作用
Xuemin Chen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2447–2458,
16
A multicentre study for determination of epidemiological cut-off values for Candida auris with EUCAST broth microdilution reference methodology
采用EUCAST肉汤微量稀释参考方法进行耳念珠菌流行病学临界值的多中心测定研究
Joseph Meletiadis and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2459–2465,
17
Impact of vancomycin resistance on attributable mortality among Enterococcus faecium bloodstream infections: propensity score analysis of a large, multicentre retrospective study
万古霉素耐药对屎肠球菌血流感染归因死亡率的影响：一项大型多中心回顾性研究的倾向评分分析
M Del Monte and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2466–2473,
18
Dynamics of dual CMV and EBV co-reactivation and emergence of resistance in an HSCT recipient
异基因造血干细胞移植受者中CMV和EBV双重再激活的动态变化及耐药性的出现
Martyna Pociupany and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2474–2483,
19
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy
意大利米兰多西环素暴露后预防（DoxyPEP）使用者中用于治疗细菌性性传播感染的抗菌药物使用情况
Angelo Roberto Raccagni and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2484–2486,
20
Comparing the mortality of patients with sepsis using empirical piperacillin/tazobactam and cefepime: analysis of the MIMIC-IV database
使用经验性哌拉西林/他唑巴坦和头孢吡肟的脓毒症患者死亡率比较：基于MIMIC-IV数据库的分析
Yongseop Lee and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2487–2495,
21
Transmitted drug resistance profiles among people living with HIV-1 in Henan province, China, 2024
2024年中国河南省HIV-1感染者传播耐药情况
Jinjin Liu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2496–2502,
22
Fluctuations in copy number of the class A carbapenemase gene blaFRI appear to confer high-level carbapenem resistance
A类碳青霉烯酶基因blaFRI拷贝数的波动似乎赋予了高水平碳青霉烯耐药性
Makiko Noda and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2503–2512,
23
In vitro activity of ceftobiprole plus ampicillin against Enterococcus faecalis causing infective endocarditis: phenotypic and genotypic characterization
头孢比罗联合氨苄西林对引起感染性心内膜炎的粪肠球菌的体外活性：表型和基因型特征
Clara Moretó-Castellsaguéand others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2513–2523,
24
Paradoxical interaction between dalbavancin and β-lactams against endocarditis-associated Enterococcus faecalis clinical isolates
达巴万星与β-内酰胺类药物对心内膜炎相关粪肠球菌临床分离株的矛盾相互作用
David Luque Paz and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2524–2529,
25
Comparative evaluation of broth microdilution and gradient diffusion methods in Burkholderia cepacia complex susceptibility testing: implications of transitioning to ECV-based interpretation
伯克霍尔德菌复合群药敏试验中肉汤微量稀释法和梯度扩散法的比较评估：向基于ECV解释转变的影响
Wenjie Cui and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2530–2540,
26
Strengthening antimicrobial resistance diagnostics in National Reference Laboratories across One Health in South and Southeast Asia: impact of external quality assessment and targeted follow-up
加强南亚和东南亚“同一健康”国家参考实验室的抗菌药物耐药性诊断能力：外部质量评估和针对性随访的影响
Freshwork Ayalew Abegaz and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2541–2549,
RESEARCH LETTERS（研究快信）
27
TDM-guided meropenem/vaborbactam-based therapy for successful treatment of intra-abdominal and bloodstream infection caused by KPC-producing ceftazidime/avibactam-resistant Klebsiella pneumoniae in a paediatric liver transplant recipient
治疗药物监测指导下的美罗培南/瓦博巴坦疗法成功治疗儿童肝移植受者中产KPC且对头孢他啶/阿维巴坦耐药的肺炎克雷伯菌引起的腹腔和血流感染
Giovanni Mulé and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2550–2552,
28
Novel tmexC7D2-toprJ5 gene cluster and transposon Tn7759 carrying blaVIM-2 and blaOXA-10 genes in a carbapenem-resistant Pseudomonas putida from urban sewage
城市污水中碳青霉烯耐药恶臭假单胞菌中携带blaVIM-2和blaOXA-10基因的新型tmexC7D2-toprJ5基因簇和转座子Tn7759
Xinyuan Qiu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2552–2555,
29
Characterization of multiresistance gene optrA in Bacillus subtillis from China
中国枯草芽孢杆菌中多重耐药基因optrA的特征分析
Yongliang Che and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2555–2557,
30
Genomic characterization of a multidrug-resistant Mammaliicoccus sciuri strain isolated from urine of a patient from China
从中国患者尿液中分离出的一株多重耐药马氏鼠球菌的基因组特征
Fuqiang Ye and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2558–2560,
LETTERS TO THE EDITOR（致编辑的信）
31
Comment on: Isavuconazole therapeutic drug monitoring and association with adverse events
关于“艾沙康唑治疗药物监测及其与不良反应的关联”的评论
Mi Zhou and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2561–2562,
32
Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalised patients with pneumonia: a nationwide retrospective cohort study
关于“住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究”的评论
Satoru Mitsuboshi
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Page 2563,
33
Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—authors’ response
住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究——作者回复
Jumpei Taniguchi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2563–2564,
Journal of Antimicrobial Chemotherapy Volume 80, Issue 10抗菌化疗杂志 80卷 10期
https://academic.oup.com/jac/issue
REVIEWS（综述）
1
Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead
长效卡博特韦和利匹韦林治疗HIV感染者的现状与未来挑战
Luis Buzón-Martín and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2565–2586,
2
Systematic reviews and the Journal of Antimicrobial Chemotherapy; past, present and future. A systematic reappraisal
系统综述与《抗菌化疗杂志》：过去、现在与未来——系统再评估
James C Hurley
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2587–2596,
SYSTEMATIC REVIEWS（系统综述）
3
Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology
研究肺结核治疗的肺内药代动力学：方法学的系统综述
Isabella van der Feltz and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2597–2608,
4
Global prevalence of nitrofurantoin-resistant uropathogenic Escherichia coli (UPEC) in humans: a systematic review and meta-analysis
全球人类中耐呋喃妥因的尿路致病性大肠埃希菌（UPEC）流行率：系统综述与荟萃分析
Christopher Larkin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2609–2621,
ORIGINAL RESEARCH（研究论著）
5
Is ampicillin plus cephalosporins a therapeutic option for Ampicillin-Susceptible Enterococcus faecium?
氨苄青霉素联合头孢菌素是否为氨苄青霉素敏感的粪肠球菌的治疗选择？
Paula Bierge and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2622–2629,
6
Therapeutic efficacy monitoring of pyronaridine–artesunate (Pyramax®) in treating uncomplicated Plasmodium falciparum malaria in Gia Lai province, Vietnam from 2022 to 2023
2022-2023年越南嘉莱省青蒿琥酯-吡咯尼抗（Pyramax®）用于无并发症恶性疟原虫疟疾的治疗效果监测
Nguyen Van Thanh and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2630–2634,
7
Effectiveness of piperacillin/tazobactam loading dose for extended infusion dosing among patients with Gram-negative bacteraemia
哌拉西林/他唑巴坦负荷剂量用于革兰氏阴性菌血症患者延长输注给药的有效性
Savan Patel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2635–2643,
8
Intrapulmonary concentrations of ceftobiprole high doses administered by continuous infusion in critically ill patients with community-acquired pneumonia
连续输注大剂量头孢比罗在社区获得性肺炎危重患者中的肺内浓度
Claire Roger and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2644–2653,
9
Cefixime versus benzathine penicillin G for the treatment of early syphilis—a randomized, controlled open label trial
头孢克肟与苄星青霉素G治疗早期梅毒的随机对照开放标签试验
Tamara Klementová and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2654–2658,
10
Trends in antifungal use among hospitalized patients in the USA, 2018–23
2018-2023年美国住院患者抗真菌药物使用趋势
Dallas J Smith and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2659–2664,
11
Clinical impact of the BCID2 and rapid AST VITEK® REVEALTM on antibiotic optimisation in critically ill patients with Gram-negative bloodstream infections: a quasi-experimental pre/post interventional study
BCID2和快速AST VITEK® REVEALTM对革兰氏阴性菌血流感染危重患者抗生素优化的临床影响：一项准实验性前后干预研究
Louis Oudiane and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2665–2675,
12
In vitro activity of thiamphenicol against drug-susceptible and drug-resistant strains of Mycoplasma genitalium
甲砜霉素对药物敏感和耐药生殖支原体菌株的体外活性
Sofie Skovmand and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2676–2681,
13
A priori optimization of levofloxacin dose regimen based on a population pharmacokinetics model
基于群体药代动力学模型的左氧氟沙星剂量方案先验优化
Emmanuel Enard and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2682–2692,
14
Model-informed individualized administration of ceftazidime–avibactam in critically ill patients: population pharmacokinetics studies and a parametric time-to-event analysis
危重患者头孢他啶-阿维巴坦的模型知情个体化给药：群体药代动力学研究和参数时间事件分析
Tingting Wu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2693–2704,
15
Development of blood culture time-to-positivity as a pharmacodynamic indicator for monitoring antibiotic therapy against MDR Gram-negative bacteria
开发血培养阳性时间作为监测针对多重耐药革兰氏阴性菌抗生素治疗的药效动力学指标
Irene Zaghi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2705–2713,
16
In vivo activity of ceftibuten-ledaborbactam oral combination against serine-β-lactamase-producing Enterobacterales: an assessment in the pyelonephritis and cystitis murine model
头孢布坦-莱达博巴坦口服联合用药对产丝氨酸-β-内酰胺酶肠杆菌科细菌的体内活性评估：在肾盂肾炎和膀胱炎小鼠模型中的评估
Christina Koenig and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2714–2718,
17
Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial
健康受试者静脉注射后口服奥马环素的粪便药代动力学、微生物组和胆汁酸变化：一项1期临床试验
Jinhee Jo and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2719–2726,
18
Interlaboratory comparison of a dried blood spot assay for antiretroviral adherence: implications for clinical application
抗逆转录病毒治疗依从性干血斑检测法的实验室间比对：对临床应用的启示
Nathan Engel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2727–2731,
19
A multicentre real-life prospective cohort study on effectiveness, durability and safety of long-acting injectable cabotegravir and rilpivirine in northern Italy: the LONGITUDE study
意大利北部长效注射用卡博特韦和利匹韦林有效性、持久性和安全性的现实中多中心前瞻性队列研究：LONGITUDE研究
Maria Mazzitelli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2732–2741,
20
Assessment of the risk of developing cefepime-induced abnormal liver enzyme levels using the albumin–bilirubin score and fibrosis-4 index: a single-centre retrospective case–control study
使用白蛋白-胆红素评分和纤维化-4指数评估头孢吡肟诱导的肝酶水平异常发生风险：一项单中心回顾性病例对照研究
Hiroki Katsu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2742–2751,
21
Clinical course of patients with bloodstream infections enrolled in the BALANCE clinical trial
BALANCE临床试验中血流感染患者的临床病程
Sean W X Ong and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2752–2758,
22
Comparative outcomes of polymyxins in neurocritical care patients with carbapenem-resistant Gram-negative bacterial pneumonia: a retrospective cohort study
神经重症患者中多黏菌素治疗碳青霉烯类耐药革兰氏阴性菌肺炎的结果比较：一项回顾性队列研究
Qian Zeng and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2759–2772,
23
Distinct population structure and genomic context of NarAB between broiler and human clinical Enterococcus isolates
肉鸡和人类临床分离的粪肠球菌中NarAB的不同群体结构和基因组背景
Jayanth Balakuntla and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2773–2781,
24
Population pharmacokinetics of bictegravir in real-world people with HIV
现实中HIV感染者比克替拉韦的群体药代动力学
Pierre Ekobena and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2782–2789,
25
Rifampicin concentrations throughout the entire treatment duration of active tuberculosis; impact of sex and body mass index
活动性肺结核整个治疗期间利福平浓度：性别和体重指数的影响
Teres Samuelsson and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2790–2798,
26
Performance of disc diffusion and gradient strip test on different Mueller–Hinton agar media plates and ComASP® and Bruker UMIC® Cefiderocol Microdilution Panels for cefiderocol susceptibility testing in carbapenem-resistant Pseudomonas aeruginosa
在碳青霉烯类耐药铜绿假单胞菌中对头孢地尔敏感性测试使用不同穆勒-欣顿琼脂培养基平板和ComASP®及Bruker UMIC®头孢地尔微量稀释板的纸片扩散法和梯度条带测试的性能
Stefano Mancini and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2799–2806,
27
Placental transfer of medications to treat COVID-19, molnupiravir, favipiravir and nirmatrelvir/ritonavir, in the ex vivo human cotyledon model
在离体人类绒毛叶模型中治疗COVID-19的药物莫努匹拉韦、法维拉韦和奈玛特韦/利托那韦的胎盘转移
Solene Labaye and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2807–2813,
28
Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms
针对具有多种耐药机制的高度耐药鲍曼不动杆菌患者分离株的含头孢地尔抗生素联合用药的协同作用
Justin Halim and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2814–2824,
29
Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015–22: experience from an HIV clinic in Paris, France
2015-2022年药物减量抗逆转录病毒策略的采用情况及对成本的影响：来自法国巴黎一家HIV诊所的经验
L Sagaon-Teyssier and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2825–2833,
30
Molecular characterization of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae susceptible to delafloxacin
对达拉氟沙星敏感的侵袭性临床肺炎链球菌分离株中氟喹诺酮耐药性的分子特征
Emilia Cercenado and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2834–2843,
31
Genomic structure of class 1 and 2 integrons in non-typhoidal Salmonella isolated from food animals and related meat products in the USA
美国食品动物及其相关肉类产品中分离的非伤寒沙门氏菌1类和2类整合子的基因组结构
Chih-Hao Hsu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2844–2853,
32
Characterization of blaOXA-542-mediated carbapenem resistance in Acinetobacter baumannii
鲍曼不动杆菌中blaOXA-542介导的碳青霉烯类耐药性的特征
Jingchen Hao and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2854–2861,
33
Phenotypic and genotypic profiles of clinical isolates of various Nocardia species to carbapenems and fluoroquinolones
各种诺卡氏菌属临床分离株对碳青霉烯类和氟喹诺酮类的表型和基因型特征
Jing Yang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2862–2872,
RESEARCH LETTERS（研究快报）
34
Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option?
奥利他万星治疗粪肠球菌复发性心内膜炎患者：一种新的治疗选择？
Giulia Turicchi and Marco Bongiovanni
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2873–2874,
35
The catA1 chloramphenicol resistance gene originated in Atlantibacter hermannii
catA1氯霉素耐药基因起源于大西洋菌属赫尔曼尼菌
Robert A Moran and Ruth M Hall
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2874–2876,
36
Horizontal transmission of a multidrug-resistant IncM1 plasmid harbouring blaOXA-48 and blaCTX-M-14b among patient microbiotas
携带blaOXA-48和blaCTX-M-14b的多重耐药IncM1质粒在患者微生物群中的水平传播
Roberto Sierra and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2876–2879,
37
Antimicrobial activity of temocillin on ceftriaxone-resistant and ceftriaxone-susceptible isolates of Neisseria gonorrhoeae
替莫西林对头孢曲松耐药和头孢曲松敏感淋病奈瑟菌分离株的抗菌活性
Julie Brousseau and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2879–2881,
LETTERS TO THE EDITOR（致编辑的信）
38
Comment on: Bactericidal activity of antibiotic combinations against clinical isolates of Enterococcus gallinarum and Enterococcus casseliflavus
述评：抗生素联合用药对临床分离的鸡肠球菌和粪肠球菌的杀菌活性
Karl Oldberg and Magnus Rasmussen
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2882–2883,
39
Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study
述评：住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究
Giancarlo Ceccarelli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2884–2885,
40
Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—right to reply—authors’ response
住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究——作者回应权——作者回复
Jumpei Taniguchi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2885–2886,
Journal of Antimicrobial Chemotherapy Volume 80, Issue Supplement_4抗菌化疗杂志 80卷 增刊4期
https://academic.oup.com/jac/issue/80/Supplement_4
SUPPLEMENT（补充）
Two Decades of BSAC Resistance Surveillance
英国抗菌化疗学会二十年耐药性监测
FOREWORD（前言）
1
Two Decades of BSAC Resistance Surveillance
英国抗菌化疗学会二十年耐药性监测
James C Hurley and Alan P Johnson
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Page iv1,
SUPPLEMENT PAPERS（补充论文）
2
Two decades of resistance surveillance by the British Society for Antimicrobial Chemotherapy: design, development, delivery, deficiencies and future directions
英国抗菌化疗学会二十年耐药性监测：设计、发展、实施、不足与未来方向
Alasdair P MacGowan and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv2–iv6,
3
The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: methods and limitations
英国抗菌化疗学会耐药性监测项目：方法与局限性
Michael Allen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv7–iv21,
4
Antimicrobial resistance among Gram-positive agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019
英国和爱尔兰地区革兰氏阳性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年）
Rosy Reynolds and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv22–iv35,
5
Antimicrobial resistance among Gram-negative agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019
英国和爱尔兰地区革兰氏阴性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年）
Rosy Reynolds and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv36–iv48,
6
Antimicrobial resistance among agents of hospital-acquired lower respiratory tract infection in the UK and Ireland: trends from 2008/2009 to 2018/2019
英国和爱尔兰地区医院获得性下呼吸道感染病原体的抗菌药物耐药性趋势（2008/2009 - 2018/2019年）
Rosy Reynolds and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv49–iv59,
7
Antimicrobial resistance among agents of community-associated lower respiratory tract infection in the UK and Ireland: trends from 1999/2000 to 2018/2019
英国和爱尔兰地区社区获得性下呼吸道感染病原体的抗菌药物耐药性趋势（1999/2000 - 2018/2019年）
Rosy Reynolds and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv60–iv71,
8
Trends of serotypes and resistance among Streptococcus pneumoniae in the UK and Ireland (1999–2019)
英国和爱尔兰地区肺炎链球菌血清型及耐药性趋势（1999 - 2019年）
Carolyne Horner and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv72–iv86,
9
Applications and benefits of the British Society for Antimicrobial Chemotherapy Resistance Surveillance Project—legacy and future
英国抗菌化疗学会耐药性监测项目的应用与益处——成果与未来
Benjamin J Parcell and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv87–iv95,
Journal of Antimicrobial Chemotherapy Volume 80, Issue 11抗菌化疗杂志 80卷 11期
https://academic.oup.com/jac/issue
VIEWPOINTS（观点）
1
Modification of antimicrobial susceptibility testing methods
抗菌药物敏感性检测方法的修改
Ian Morrissey and Jean B Patel
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2887–2888,
2
Viewpoint: global antimicrobial stewardship accreditation is needed: the experience in Kentucky, USA
观点：需要建立全球抗菌药物管理认证体系：美国肯塔基州的经验
Ashley M Wilde and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2889–2891,
REVIEWS（综述）
3
Phages connect the biological dots of antimicrobial resistance: from genesis and spread to alternative treatment modules
噬菌体揭示抗菌药物耐药性的生物学脉络：从起源与传播到替代治疗模式
Cleo Anastassopoulou and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2892–2901,
4
Molecular drivers of fusion plasmid: mechanistic insights and evolutionary implications
融合质粒的分子驱动因素：机制见解与进化意义
Ziyi Liu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2902–2911,
ORIGINAL RESEARCH（研究论著）
5
Emergence of livestock-associated MRSA clonal complex 398 in Thailand’s swine industry
泰国养猪业中出现与牲畜相关的MRSA克隆复合体398
Pawarut Narongpun and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2912–2917,
6
Peripheral neuropathy during long-term suppressive therapy with tedizolid: a case series
长期使用替达拉韦抑制治疗期间出现周围神经病变：系列病例报告
Tomaso Beringheli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2918–2922,
7
Low bacterial metabolism as a central mechanism of antimicrobial resistance and potential therapeutic target of staphylococcal biofilms in ventricular assist device driveline infections
细菌低代谢作为抗菌药物耐药性的核心机制及心室辅助装置驱动线感染中葡萄球菌生物膜的潜在治疗靶点
Yao Sun and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2923–2933,
8
The pivotal role of acnA in linking carbon metabolism to virulence and antimicrobial resistance in methicillin-resistant Staphylococcus aureus
acnA在连接碳代谢与耐甲氧西林金黄色葡萄球菌的毒力和抗菌药物耐药性中的关键作用
Jiahui Li and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2934–2944,
9
Pharmacokinetics of rifampicin and isoniazid in patients with HIV–tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292–RIFAVIRENZ sub-study
接受以依非韦伦为基础的抗逆转录病毒治疗的HIV-结核病共感染患者中利福平和异烟肼的药代动力学：ANRS12292-RIFAVIRENZ子研究
Thibaut Gelé and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2945–2953,
10
Novel mutations associated with clofazimine resistance in Mycobacterium intracellulare
胞内分枝杆菌中与氯法齐明耐药相关的新型突变
Xiuzhi Jiang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2954–2957,
11
Physiologically informed in vitro framework reveals context-dependent combinatory activity of niclosamide–colistin against Gram-negative bacteria
基于生理信息的体外框架揭示了针对革兰氏阴性菌的硝基咪唑-多粘菌素组合的情境依赖性活性
Mariana Romero-Gonzalez and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2958–2969,
12
In vitro evolution provides insights into mechanisms of Mycoplasma genitalium resistance to moxifloxacin
体外进化揭示生殖支原体对莫西沙星的耐药机制
Teck-Phui Chua and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2970–2977,
13
The toxin–antitoxin system SavRS contributes to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus by mediating cell wall thickening
毒素-抗毒素系统SavRS通过介导细胞壁增厚促进万古霉素中间型金黄色葡萄球菌对万古霉素的耐药性
Weifeng Xu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2978–2988,
14
Molecular insights into carbapenemase-producing Enterobacterales from Senegal
塞内加尔产碳青霉烯酶肠杆菌目细菌的分子特征
Ousmane Sow and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2989–3000,
15
Population pharmacokinetic model of linezolid and its metabolite PNU-142300 in elderly patients
老年患者中利奈唑胺及其代谢产物PNU-142300的群体药代动力学模型
Xianglong Chen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3001–3010,
16
In vitro activity of contezolid and other comparators against clinical Staphylococcus and Enterococcus: a multicenter study in China
在中国开展的一项多中心研究中，康替唑胺及其他对照药物对临床分离的金黄色葡萄球菌和肠球菌的体外活性
Rongqi Lu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3011–3020,
17
Co-existence of the oxazolidinone resistance genes cfr and optrA on a novel multiresistance plasmid from a methicillin-resistant Macrococcoides bohemicum strain
从一株耐甲氧西林的马科考代菌属波希米亚菌株中发现的携带恶唑烷酮耐药基因cfr和optrA的新型多重耐药质粒
Yao Zhu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3021–3025,
18
Multidrug resistance and recurrence in urinary bacteraemia among cancer patients
癌症患者中尿路菌血症的多药耐药性和复发情况
Ignacio Grafia and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3026–3033,
19
Rapid replacement of blaKPC variant in ST11 carbapenem-resistant and hypervirulent Klebsiella pneumoniae contributed to ceftazidime/avibactam resistance during severe in vivo infection
在严重的体内感染期间，ST11型碳青霉烯耐药且高毒力的肺炎克雷伯菌中blaKPC变体的快速替代导致头孢他啶/阿维巴坦耐药
Ping Yang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3034–3042,
20
Potential human health risk of carbapenem-non-susceptible Pseudomonas aeruginosa from companion animals
伴侣动物中碳青霉烯类不敏感铜绿假单胞菌对人类健康的潜在风险
Jirachaya Toyting-Hiraishi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3043–3056,
21
Assessment of an LC coupled with tandem MS (LC-MS/MS) tool in the detection of antimicrobial resistance mechanisms in Enterobacterales
液相色谱-串联质谱（LC-MS/MS）工具在检测肠杆菌目细菌抗菌药物耐药机制中的应用评估
Anna Witkowska and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3057–3064,
22
Multidrug efflux pumps and innate azole resistance of Mucor lusitanicus
毛霉属葡萄牙菌的多药外排泵及其固有唑类耐药性
Stephanie Toepfer and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3065–3078,
23
Ivermectin dosing for children under 2 years
2岁以下儿童的伊维菌素剂量
Wenyu Yang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3079–3081,
24
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort
一线拉米夫定/多替拉韦抗逆转录病毒疗法在HIV感染者中的有效性：来自ICONA基金会队列的现实数据
Alessandra Vergori and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3082–3091,
25
Eligibility and factors associated with long-acting injectable cabotegravir-rilpivirine initiation in an urban academic HIV clinic
城市学术型HIV诊所中长效注射用卡博特韦-利匹韦林启动的资格及关联因素
Geoffroy Liegeon and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3092–3100,
26
Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry
在接受抑制性抗逆转录病毒治疗的高度治疗经验丰富和多药耐药个体中，HIV-1 DNA耐药演变的评估：来自PRESTIGIO登记处的纵向研究
D Armenia and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3101–3106,
27
Sequential antibiotic exposure restores antibiotic susceptibility
序贯抗生素暴露恢复抗生素敏感性
Farhan R Chowdhury and Brandon L Findlay
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3107–3117,
28
Dermatological adverse effects of doxycycline as post-exposure prophylaxis for sexually transmitted infections among men who have sex with men: real-world findings from a multicentre study
在男男性行为者中，使用多西环素作为性传播感染暴露后预防的皮肤科不良反应：一项多中心研究的现实发现
Ling-Ya Chen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3118–3122,
29
Phenotype–genotype discordance in antimicrobial resistance profiles of Gram-negative uropathogens recovered from catheter-associated urinary tract infections in Egypt
埃及导管相关尿路感染中分离的革兰氏阴性尿路病原菌抗菌药物耐药性表型-基因型不一致性
Mohamed Eladawy and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3123–3132,
30
How should APOBEC3-induced resistance mutations be considered in the management of antiretroviral therapy?
在抗逆转录病毒治疗管理中，应如何考虑APOBEC3诱导的耐药突变？
Marie Gilbert and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3133–3138,
31
In vitro evaluation of olorofim and antifungal combinations against Aspergillus and Candida species
奥洛芬和抗真菌药物组合对曲霉菌和念珠菌属的体外评价
Corinne Pinder and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3139–3149,
32
Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis
在侵袭性肺曲霉病小鼠模型中，泊沙康唑与奥洛芬之间的拮抗作用
Christopher A Darlow and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3150–3159,
33
High level of archived and circulating HIV-1 drug resistance mutations in adolescents with a detectable viremia in Cameroon
喀麦隆可检测到病毒载量的青少年中HIV-1药物耐药突变的存档和循环水平较高
Armando B D Djiyou and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3160–3164,
RESEARCH LETTERS（研究快讯）
34
SCY-247, a novel second-generation triterpenoid antifungal, demonstrates high in vitro activity against genetically diverse Candida auris isolates, including FKS1 mutants
新型第二代三萜类抗真菌药物SCY-247对包括FKS1突变体在内的多种基因型耳道假丝酵母菌显示出高体外活性
Bram Spruijtenburg and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3165–3166,
35
Drug–drug interactions between tirzepatide and antiretrovirals: time to reassess and reassure?
替西帕肽与抗逆转录病毒药物之间的药物-药物相互作用：是时候重新评估和安心了吗？
Andrea Poloni and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3167–3168,
36
Does the use of topical azoles have an impact on antifungal resistance?
局部使用唑类药物对抗真菌耐药性有影响吗？
Jean-Yves Maillard
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3168–3186,
37
Leakage of cabotegravir and rilpivirine in HIV patients receiving long-acting injectable antiretroviral therapy
接受长效注射用抗逆转录病毒治疗的HIV患者中卡博特韦和利匹韦林的泄漏情况
Samir Benkouiten and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3187–3188,
CORRECTION（更正）
38
Correction to: Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae
更正：对四种产NDM且之前未接触过头孢地洛的耐药肺炎克雷伯菌引起的血流感染的临床和微生物学分析
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Page 3189,
100 项与 两性霉素B 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 利什曼病 | 日本 | 2009-06-17 | |
| 粒细胞减少性发热 | 日本 | 2006-04-20 | |
| 念珠菌病 | 日本 | 1997-01-31 | |
| 侵袭性真菌感染 | 日本 | 1963-04-18 | |
| 真菌病 | - | 1958-01-01 | |
| 复杂的尿路感染 | 中国 | - | - |
| 细菌性心内膜炎 | 中国 | - | - |
| 脑膜炎 | 中国 | - | - |
| 脓毒症 | 中国 | - | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 隐球菌脑膜炎 | 临床3期 | - | 2023-01-01 | |
| 肺部疾病 | 临床3期 | 美国 | 2005-10-01 | |
| 侵袭性念珠菌病 | 临床2期 | - | 2020-01-01 | |
| 侵袭性曲霉菌病 | 临床2期 | - | 2020-01-01 | |
| 急性淋巴细胞白血病 | 临床2期 | - | 2019-08-01 | |
| 急性髓性白血病 | 临床2期 | - | 2019-08-01 | |
| 外阴阴道念珠菌病 | 临床2期 | 美国 | 2016-11-01 | |
| 酵母菌感染 | 临床2期 | 美国 | 2016-11-01 | |
| 慢性皮肤黏膜念珠菌病 | 临床2期 | 美国 | 2016-09-27 | |
| 口腔念珠菌病 | 临床2期 | 美国 | 2001-08-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
N/A | 32 | ABCD nebulized inhalation combined with intravenous injection | 淵鏇築鏇顧壓獵襯糧鏇(膚構積鬱範鹽鑰製構壓) = slightly lower in the combined therapy group than in the intravenous therapy group (1675 vs 1800, P=0.611), although the difference was not statistically significant. 築網觸鏇襯艱艱窪顧鑰 (選獵窪構鏇淵選鑰選醖 ) 更多 | 积极 | 2025-07-01 | ||
ABCD intravenous injection | |||||||
N/A | 503 | 簾衊夢餘夢網蓋廠鹹淵(遞齋築鏇淵廠鹹積糧繭) = 糧鹽獵艱憲憲遞餘襯製 醖選糧網築鹹膚衊襯憲 (鹹鏇膚艱壓憲淵繭淵構 ) 更多 | 积极 | 2025-05-01 | |||
临床2期 | 118 | single dose of L-AmB (Single Dose of L-AmB) | 製鑰齋網壓構餘衊網積 = 遞鑰窪遞衊淵廠夢構窪 夢鏇築醖網艱夢廠獵齋 (築膚齋憲壓鏇願廠夢憲, 鹽選餘範觸繭顧觸憲築 ~ 衊鏇壓範築網願觸鏇遞) 更多 | - | 2025-03-14 | ||
(2 Doses of L-AmB) | 製鑰齋網壓構餘衊網積 = 膚鬱觸築願艱壓選鏇顧 夢鏇築醖網艱夢廠獵齋 (築膚齋憲壓鏇願廠夢憲, 壓鹽鏇艱鏇廠壓鹽膚糧 ~ 範鏇艱鏇鑰範艱膚鏇壓) 更多 | ||||||
临床4期 | 55 | 簾糧顧選蓋積窪壓獵廠(憲膚鹽夢遞窪襯構積獵) = 餘廠鏇觸獵積構積窪廠 鏇窪製範齋鏇鬱醖遞蓋 (蓋顧鹹廠衊築廠製鹹窪 ) 更多 | 积极 | 2025-03-11 | |||
临床1/2期 | 隐球菌脑膜炎 human immunodeficiency virus (HIV) | 498 | Liposomal Amphotericin B | 蓋壓願淵範構構鹹積鏇(壓襯簾廠鏇顧鑰衊襯觸) = 蓋廠遞廠窪壓襯構夢網 壓鏇鏇夢網齋鑰夢選夢 (憲艱鹽選齋膚顧鑰範鬱, 0.355 ~ 0.634) 更多 | 积极 | 2025-02-05 | |
蓋壓願淵範構構鹹積鏇(壓襯簾廠鏇顧鑰衊襯觸) = 獵鬱網鏇構襯衊蓋範築 壓鏇鏇夢網齋鑰夢選夢 (憲艱鹽選齋膚顧鑰範鬱, 0.360 ~ 0.445) 更多 | |||||||
N/A | 21 | (Group A (poor response to other antifungal drugs)) | 積觸簾獵遞夢觸積蓋糧(範繭廠選襯簾築簾鏇顧) = 範醖觸壓積積範憲淵齋 襯鏇築鹽鬱襯範淵積鹹 (鹽鹽齋積艱膚襯蓋積鏇 ) | 积极 | 2024-05-14 | ||
(Group B (cannot tolerate adverse reactions)) | 積觸簾獵遞夢觸積蓋糧(範繭廠選襯簾築簾鏇顧) = 簾積願衊遞選衊觸範窪 襯鏇築鹽鬱襯範淵積鹹 (鹽鹽齋積艱膚襯蓋積鏇 ) | ||||||
GlobeNewswire 人工标引  | N/A | 3 | 願鹹醖製壓鑰糧積簾壓(醖簾廠鏇壓鏇夢選壓鏇) = 壓遞壓積蓋鏇醖鏇網壓 壓襯廠遞壓艱遞壓願齋 (壓夢淵餘築餘窪遞淵願 ) | 积极 | 2024-03-22 | ||
GlobeNewswire 人工标引 | N/A | 19 | 積鏇憲繭蓋繭淵遞鏇蓋(願構願觸鹽襯選製鹹簾) = 遞衊醖壓蓋鏇淵夢鹹鏇 窪範鏇網廠廠淵襯衊襯 (網選壓鑰觸窪壓蓋繭願 ) 更多 | 积极 | 2024-02-26 | ||
临床1/2期 | 80 | Oral LNC Amphotericin B + Flucytosine | 艱淵淵網艱遞獵鬱衊壓(鏇壓壓壓糧鹹網蓋觸廠) = 淵積顧糧鏇繭繭餘獵淵 衊膚蓋糧觸鑰簾簾醖膚 (繭艱網蓋醖淵遞網積網 ) 更多 | - | 2023-08-22 | ||
IV Amphotericin + Flucytosine | 艱淵淵網艱遞獵鬱衊壓(鏇壓壓壓糧鹹網蓋觸廠) = 鑰淵顧鹹範衊蓋壓艱簾 衊膚蓋糧觸鑰簾簾醖膚 (繭艱網蓋醖淵遞網積網 ) 更多 | ||||||
N/A | - | Liposomal amphotericin (LAmB) | 糧蓋構鑰積構衊廠繭窪(鏇選壓鏇網壓膚選觸鹽) = 簾製構醖憲範構齋鹽繭 餘齋願襯鑰願艱積襯繭 (繭簾觸遞艱構範鏇糧蓋 ) 更多 | - | 2023-03-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用